| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERA.09.2 |
| P698 | PubMed publication ID | 19374599 |
| P50 | author | Armando Santoro | Q56335956 |
| P2093 | author name string | Paolo Andrea Zucali | |
| Fabio De Vincenzo | |||
| Matteo Simonelli | |||
| P2860 | cites work | Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer | Q24528253 |
| Mesothelin targeted cancer immunotherapy | Q24656242 | ||
| Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems | Q24679305 | ||
| Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions | Q28262540 | ||
| Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study | Q28269021 | ||
| MESOMARK: a potential test for malignant pleural mesothelioma | Q28287442 | ||
| Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer | Q28299511 | ||
| mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats | Q28377808 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed | Q33274781 | ||
| Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study | Q33329809 | ||
| Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study | Q33348171 | ||
| Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma | Q33362340 | ||
| Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma | Q33378691 | ||
| Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. | Q33379936 | ||
| SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma | Q33946963 | ||
| The cytology of malignant mesothelioma | Q33956847 | ||
| Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma | Q34214330 | ||
| Cancer chemotherapy--ribonucleases to the rescue | Q34254671 | ||
| Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies | Q34329871 | ||
| Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. | Q34457473 | ||
| Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients | Q34485292 | ||
| The pathogenesis of mesothelioma | Q34522971 | ||
| Positron emission tomography predicts survival in malignant pleural mesothelioma. | Q34568723 | ||
| Validation of genomics-based prognostic tests in malignant pleural mesothelioma | Q34715788 | ||
| Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas | Q34759870 | ||
| Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. | Q34760305 | ||
| The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system. | Q34832348 | ||
| Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis | Q34979814 | ||
| Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma | Q35184119 | ||
| Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development | Q35789268 | ||
| Bortezomib as a potential treatment for prostate cancer | Q35853743 | ||
| Radiology in pleural disease: state of the art. | Q35885165 | ||
| External beam radiation therapy for the treatment of pleural mesothelioma | Q35960203 | ||
| Chemotherapy options and new advances in malignant pleural mesothelioma | Q36022779 | ||
| Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma | Q36160226 | ||
| Molecular pathways in malignant pleural mesothelioma | Q36282447 | ||
| Use of imaging in the management of malignant pleural mesothelioma | Q36314277 | ||
| Antiangiogenic therapies for mesothelioma | Q36329835 | ||
| Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging | Q36504814 | ||
| Positron emission tomography as an imaging biomarker | Q36531392 | ||
| New technologies and directed agents for applications of cancer imaging | Q36531402 | ||
| The Met pathway: master switch and drug target in cancer progression | Q36549360 | ||
| Biology and management of malignant pleural mesothelioma. | Q36600505 | ||
| VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. | Q36641154 | ||
| A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. | Q36646087 | ||
| Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial | Q36727434 | ||
| Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma | Q36755228 | ||
| Update on the molecular biology of malignant mesothelioma | Q36755500 | ||
| Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion | Q38431410 | ||
| Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study | Q38432019 | ||
| Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group | Q39214897 | ||
| Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts | Q40020180 | ||
| Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts | Q40041128 | ||
| Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. | Q40073685 | ||
| Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma | Q40128441 | ||
| Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway | Q40158294 | ||
| Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth | Q40421611 | ||
| Thalidomide in patients with malignant pleural mesothelioma | Q40430715 | ||
| Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma | Q40749578 | ||
| Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines | Q41229288 | ||
| Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma | Q43558001 | ||
| Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. | Q44267257 | ||
| Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? | Q44513200 | ||
| Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. | Q46402560 | ||
| Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma | Q46432866 | ||
| Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma | Q46548604 | ||
| The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma | Q46590733 | ||
| Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. | Q46625222 | ||
| Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma | Q46674520 | ||
| Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst | Q46726893 | ||
| Phase II study of vinflunine in malignant pleural mesothelioma | Q46942070 | ||
| Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid | Q46972335 | ||
| Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. | Q47733896 | ||
| Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma | Q47765137 | ||
| Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma | Q47971165 | ||
| Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest | Q48027510 | ||
| A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. | Q50120860 | ||
| Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. | Q51687498 | ||
| Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. | Q51687514 | ||
| A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons. | Q51941794 | ||
| Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. | Q51963887 | ||
| Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. | Q51996240 | ||
| Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. | Q53272197 | ||
| A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. | Q53369235 | ||
| Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. | Q53547668 | ||
| Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. | Q53632285 | ||
| Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. | Q53675680 | ||
| SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. | Q53854583 | ||
| Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. | Q54538240 | ||
| Mesothelin-family proteins and diagnosis of mesothelioma | Q57297479 | ||
| Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment | Q57554474 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 453-467 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Expert Review of Anticancer Therapy | Q2999044 |
| P1476 | title | Future developments in the management of malignant pleural mesothelioma | |
| P478 | volume | 9 |
| Q82154881 | Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma |
| Q35189370 | Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model |
| Q39350596 | Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma |
| Q27853165 | Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors |
| Q34549793 | Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma |
| Q52672891 | Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma. |
| Q37128016 | Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy? |
Search more.